Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial is being conducted to investigate the safety and effectiveness of a new device designed to treat urinary urge incontinence in those patients who have tried and failed two or more conservative therapies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on. |
|
| 2 | Sham Comparator | No Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bion | Device | battery powered microstimulator |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Leaks Per Day | 12 months | |
| Freedom From Major Complications | 5 years |
Not provided
Not provided
Key Inclusion Criteria:
Key Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tamara Baynham, PhD | Boston Scientific, Neuromodulation | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arizona Health Sciences Center (University of Arizona) | Tucson | Arizona | 85724 | United States | ||
| The Department of Urology, Stanford University Medical Center |
Although enrollment numbers totaled 148 subjects, the total number of implanted subjects were used for the analysis. Total number of implanted subjects is 87.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Treatment | Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on. |
| FG001 | Control |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Stanford |
| California |
| 94305-5118 |
| United States |
| Milestone Medical Research | Englewood | Colorado | 80112 | United States |
| Bladder Control Center of Norwalk | Norwalk | Connecticut | 06850 | United States |
| Walter Reed Army Medical Center, Division of Pelvic Medicine and Reconstructive Surgery | Washington D.C. | District of Columbia | 20307-5001 | United States |
| William Beaumont Hospital | Royal Oak | Michigan | 48073 | United States |
| Cornerstone Medical Specialty Center | Woodbury | Minnesota | 55125 | United States |
| The Pelvic and Sexual Health Institute (affiliated with Graduate Hospital) | Philadelphia | Pennsylvania | 19146 | United States |
| Dallas Center for Pelvic Medicine | Dallas | Texas | 75231 | United States |
| Baylor College of Medicine | Houston | Texas | 77030 | United States |
| Sound Urological Associates | Edmonds | Washington | 98026 | United States |
No Stimulation from post-implant until 45 days post-implant. Stimulation On from 45 days post-implant and on. |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Control | No stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on. |
| BG001 | Treatment | Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Leaks Per Day | Posted | Mean | Standard Deviation | Number of Leaks Per Day | 12 months |
|
|
| ||||||||||||||||||||||||||||||
| Primary | Freedom From Major Complications | Posted | Number | Number of Adverse Events | 5 years |
|
|
5 years
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Control | No stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on. | 0 | 42 | 35 | 42 | ||
| EG001 | Treatment | Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on. | 0 | 45 | 32 | 45 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal pain lower | Gastrointestinal disorders | MedDRA (10.1) |
| ||
| Abdominal Pain Upper | Gastrointestinal disorders | MedDRA (10.1) |
| ||
| Anal Discomfort | Gastrointestinal disorders | MedDRA (10.1) |
| ||
| Constipation | Gastrointestinal disorders | MedDRA (10.1) |
| ||
| Diarrhoea | Gastrointestinal disorders | MedDRA (10.1) |
| ||
| Proctalgia | Gastrointestinal disorders | MedDRA (10.1) |
| ||
| Adhesion | General disorders | MedDRA (10.1) |
| ||
| Implant Site Pain | General disorders | MedDRA (10.1) |
| ||
| Implant Site Paresthesia | General disorders | MedDRA (10.1) |
| ||
| Therapeutic Product Ineffective | General disorders | MedDRA (10.1) |
| ||
| Therapeutic Response Decreased | General disorders | MedDRA (10.1) |
| ||
| Cystitis | Infections and infestations | MedDRA (10.1) |
| ||
| Urinary Tract Infection | Infections and infestations | MedDRA (10.1) |
| ||
| Vaginal Infection | Infections and infestations | MedDRA (10.1) |
| ||
| Device Breakage | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Device electrical Finding | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Device Failure | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Device Migration | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Failure of Implant | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Inappropriate Device Stimulation of Tissue | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Incision Site Pain | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Procedural Pain | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Suture Related Complication | Injury, poisoning and procedural complications | MedDRA (10.1) |
| ||
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (10.1) |
| ||
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA (10.1) |
| ||
| Limb Discomfort | Musculoskeletal and connective tissue disorders | MedDRA (10.1) |
| ||
| Muscle Spasm | Musculoskeletal and connective tissue disorders | MedDRA (10.1) |
| ||
| Musculuskeletal Pain | Musculoskeletal and connective tissue disorders | MedDRA (10.1) |
| ||
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA (10.1) |
| ||
| Pain in Extremity | Musculoskeletal and connective tissue disorders | MedDRA (10.1) |
| ||
| Dysaesthesia | Nervous system disorders | MedDRA (10.1) |
| ||
| Hypoaesthesia | Nervous system disorders | MedDRA (10.1) |
| ||
| Muscle Contractions involuntary | Nervous system disorders | MedDRA (10.1) |
| ||
| Nerve Compression | Nervous system disorders | MedDRA (10.1) |
| ||
| Neurological symptom | Nervous system disorders | MedDRA (10.1) |
| ||
| Dysuria | Renal and urinary disorders | MedDRA (10.1) |
| ||
| Micturition urgency | Renal and urinary disorders | MedDRA (10.1) |
| ||
| Pollakiuria | Renal and urinary disorders | MedDRA (10.1) |
| ||
| Urge Incontinence | Renal and urinary disorders | MedDRA (10.1) |
| ||
| Genital Pain | Reproductive system and breast disorders | MedDRA (10.1) |
| ||
| Pelvic Discomfort | Reproductive system and breast disorders | MedDRA (10.1) |
| ||
| Pelvic Pain | Reproductive system and breast disorders | MedDRA (10.1) |
| ||
| Perineal Pain | Reproductive system and breast disorders | MedDRA (10.1) |
| ||
| Vaginal Pain | Reproductive system and breast disorders | MedDRA (10.1) |
| ||
| Vulval disorder | Reproductive system and breast disorders | MedDRA (10.1) |
| ||
| Scar Pain | Skin and subcutaneous tissue disorders | MedDRA (10.1) |
|
This study was limited by poor adherence to the clinical protocol and by incomplete data recovery. Analysis of efficacy-related endpoints was not possible.
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director of Clinical Operations | Boston Scientific | 866-360-4747 | Valerie.Lucero-Cimmarust@bsci.com |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| Male |
|
|